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Abstract
During metaphase, in response to improper kinetochore-microtubule
attachments, the spindle assembly checkpoint (SAC) activates the
mitotic checkpoint complex (MCC), an inhibitor of the anaphase-
promoting complex/cyclosome (APC/C). This process is orchestrated
by the kinase Mps1, which initiates the assembly of the MCC onto
kinetochores through a sequential phosphorylation-dependent
signalling cascade. The Mad1-Mad2 complex, which is required to
catalyse MCC formation, is targeted to kinetochores through a
direct interaction with the phosphorylated conserved domain 1
(CD1) of Bub1. Here, we present the crystal structure of the C-
terminal domain of Mad1 (Mad1CTD) bound to two phosphorylated
Bub1CD1 peptides at 1.75 A resolution. This interaction is mediated
by phosphorylated Bub1 Thr461, which not only directly interacts
with Arg617 of the Mad1 RLK (Arg-Leu-Lys) motif, but also directly
acts as an N-terminal cap to the CD1 a-helix dipole. Surprisingly,
only one Bub1CD1 peptide binds to the Mad1 homodimer in solu-
tion. We suggest that this stoichiometry is due to inherent asym-
metry in the coiled-coil of Mad1CTD and has implications for how
the Mad1-Bub1 complex at kinetochores promotes efficient MCC
assembly.
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Introduction
Cell division, a process by which cells duplicate themselves, along
with their DNA, is the most fundamental process of life. Faithful
chromosome segregation requires surveillance by the SAC, which,
in response to improper kinetochore-microtubule attachments,
delays anaphase onset until biorientation of attachments has been
achieved (Foley & Kapoor, 2013; Musacchio, 2015; Sacristan &
Kops, 2015). SAC activation then triggers production of the mitotic
checkpoint complex (MCC) consisting of BubR1, Bub3, Mad2 and
Cdc20 (Sudakin et al, 2001; Chao et al, 2012). The MCC functions
by binding and inhibiting the E3 ubiquitin ligase, the anaphase-
promoting complex/cyclosome (APC/C), when the APC/C is bound
by a second coactivating molecule of Cdc20 (Herzog et al, 2009;
Izawa & Pines, 2015; Alfieri et al, 2016; Yamaguchi et al, 2016).
Inhibition of the APC/C then delays premature chromosome segre-
gation by preventing APC/C-mediated degradation of two key cell
cycle regulators, cyclin B and securin (Cohen-Fix et al, 1996; Clute
& Pines, 1999).
Understanding the molecular mechanisms of how kinetochores
recruit checkpoint proteins and how each protein contributes to
the localization and stimulation of downstream components
remains a major unresolved question in the field. Recent work
points towards hierarchical recruitment of SAC proteins to the outer
kinetochore, by means of an Mps1-dependent phosphorylation
cascade, which creates a catalytic platform for MCC assembly
(Fig 1A and B) (Faesen et al, 2017; Ji et al, 2017b; Dou et al, 2019).
This begins with Mps1 phosphorylating several MELT (methionine–
glutamate–leucine–threonine) motifs on the outer kinetochore
protein Knl1, which then recruits the Bub3-Bub1 complex (London
et al, 2012; Shepperd et al, 2012; Yamagishi et al, 2012; Primorac
et al, 2013; Vleugel et al, 2015). Next, Mps1 phosphorylates Bub1 at
a central conserved domain 1 (CD1), which recruits the Mad1-Mad2
complex (London & Biggins, 2014a, 2014b; Ji et al, 2017b; Zhang
et al, 2017). Although the precise recruitment pathway of Cdc20 for
MCC formation is still debated, it is likely that Bub1, through ABBA
and KEN motifs just C-terminal to the CD1 domain, plays a role in
recruiting and repositioning Cdc20 close to the Mad1-Mad2 complex
(Diaz-Martinez et al, 2015; Lischetti et al, 2015; Di Fiore et al, 2016;
Zhang et al, 2019).
Recently, a third phosphorylation event catalysed by Mps1 was
identified at the very C-terminus of Mad1, which significantly
enhances rates of MCC formation, possibly by promoting an interac-
tion with Cdc20 and repositioning the Mad2-interacting motif (MIM)
of Cdc20 close to Mad2 (Ji et al, 2017a, 2017b). In the last step of
MCC assembly, the Mad1-Mad2 complex acts as a platform for
conversion of Mad2 in the open conformation (O-Mad2) into closed-
Mad2 (C-Mad2) through a template conversion mechanism (Sironi
et al, 2002; Luo et al, 2004; De Antoni et al, 2005; Mapelli et al,
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2007; Simonetta et al, 2009). C-Mad2 is then passed onto Cdc20 to
form the Cdc20:C-Mad2 complex which binds BubR1 with high
affinity to generate the MCC (Kulukian et al, 2009; Chao et al, 2012;
Faesen et al, 2017). Altogether, this suggests that MCC assembly
onto kinetochores requires a highly regulated Mps1-dependent
phosphorylation cascade which utilizes Bub1 as a key platform for
targeting and repositioning the catalytic engine Mad1:C-Mad2 as
well as BubR1 and Cdc20.
The importance of the phosphorylated Bub1-Mad1 complex in SAC
activation was suggested in 2000 in a study which also identified the
RLK motif of Mad1 as being essential for Mad1 kinetochore associa-
tion (Brady & Hardwick, 2000). The role of the Mad1 RLK motif and
the Bub1 CD1 domain in SAC signalling and Mad1 kinetochore target-
ing has since been well studied, and both are highly conserved across
species (Kim et al, 2012; Heinrich et al, 2014; London & Biggins,
2014a; Zhang et al, 2017; Luo et al, 2018). It was not until 2014 that a
direct interaction between Bub1CD1 and Mad1CTD in budding yeast
was shown to be dependent on phosphorylation of Bub1CD1 by Mps1
at Thr453 and Thr455 (London & Biggins, 2014a). In 2017, two inde-
pendent studies confirmed the direct interaction of human Bub1CD1-
Mad1RLK which was dependent on phosphorylation at Ser459 and
Thr461 (Ji et al, 2017b; Zhang et al, 2017). Schematics of human Bub1
and human Mad1 are shown in Fig 2A.
Because there was no structural information of the Bub1-Mad1
complex, the overall architecture and how phosphorylation
promotes specificity of the Bub1-Mad1 interaction remained
unclear. Here, we present the first structure of the human Mad1CTD
homodimer bound to two phosphorylated human Bub1CD1 peptides
at 1.75 A. We found that this interaction is dependent on pThr461
which makes direct contact with Arg617 of the conserved Mad1
RLK motif, whereas pSer459 is not involved. We were able to gain
further detailed structural insights into this interaction using NMR
spectroscopy which suggests a strikingly global conformational
change across Mad1CTD upon Bub1CD1 binding. Additionally, and to
our surprise, we discovered that in solution only one Bub1CD1
peptide binds to the Mad1CTD homodimer. We hypothesize that this
is due to an inherent asymmetry of Mad1CTD, also apparent in the
previously crystallized apo Mad1CTD homodimer (Kim et al, 2012).
This asymmetry makes only one side of the Mad1CTD dimer favour-
able for binding and might have important implications for the func-
tion of the Mad1:Mad2:Bub1:Cdc20 complex at kinetochores.
Results
Overall architecture of Bub1CD1 bound to Mad1CTD
We determined a near-atomic resolution crystal structure of the
human Mad1CTD homodimer (residues 597–718) bound to two
doubly phosphorylated Bub1 peptides comprising the CD1 domain,
A B
Figure 1. Model of MCC assembly and the Bub1-Mad1-Mad2-Cdc20 complex at kinetochores.
A Outline of the essential sequential steps of MCC assembly onto the outer kinetochore.
B A model of MCC assembly onto the outer kinetochore. MCC assembly occurs in a stepwise manner that is under the control of Mps1 and Cdk1 kinases. Several MELT
motifs on Knl1 are first phosphorylated by Mps1. pMELTs then recruit the Bub3:Bub1 complex which is then phosphorylated first by Cdk1 then by Mps1 on the Bub1 CD1
domain. Phosphorylated Bub1 then recruits the Mad1:C-Mad2 complex which then acts as a platform for O-Mad2 binding and catalyst for conversion into C-Mad2. Bub1
is likely responsible for Cdc20 targeting to kinetochores through its KEN and ABBA motifs as well BubR1 through a central Bub1-BubR1 dimerization domain. The CTD of
Mad1 is phosphorylated by Mps1 which interacts with an N-terminal tail of Cdc20. Bub1 therefore acts as a scaffold to position C-Mad2, BubR1 and Cdc20 in close
proximity for efficient MCC formation. Once formed soluble MCC then binds and inactivates the APC/C, preventing metaphase to anaphase progression.
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termed the Mad1CTD-Bub1CD1 complex (Fig 2B) (PDB: 7B1F). This is
the first reported structure of the Bub1 CD1 domain and of the
Mad1CTD-Bub1CD1 complex. The Bub1CD1 peptide sequence (resi-
dues 455-479) used in this study is shown in Fig 2A, with the two
sites of phosphorylation (Ser459 and Thr461) indicated. The highest
resolution crystal structure, belonging to space group P212121,
diffracted to 1.75 A, with one Mad1CTD-Bub1CD1 complex per asym-
metric unit. However, due to strong anisotropic diffraction, the
actual resolution is closer to 2.1 A. A summary of the data collection
and refinement statistics is given in Appendix Table S1.
In the crystal structure, two Bub1CD1 peptides are bound to the
Mad1CTD homodimer (Fig 2B). The structure of Mad1CTD when
bound to Bub1CD1 is similar overall to the previously published apo
Mad1CTD crystal structure (PDB: 4DZO) (Kim et al, 2012). Mad1CTD
is comprised of an N-terminal elongated coiled-coil, followed by a
globular head domain featuring a conserved RWD (RING, WD40,
DEAD) domain (Nameki et al, 2004; Petrovic et al, 2014). Each
monomer contains a long N-terminal a-helix (a1) forming the stem,
followed by an antiparallel b-sheet of four b-strands (b1–4), a short
helix (a2) and two C-terminal helices (a3/a4).
Bub1CD1 is largely a single a-helix, consisting of almost four turns
(Fig 2B). We were able to confidently build 21 of the 26 residues of
each Bub1CD1 peptide, with the first three and last two residues not
visible in the electron density map. The six N-terminal residues
A
B
Figure 2. Overview of the human Mad1CTD-Bub1CD1 complex.
A Schematics of full-length human Mad1 and Bub1. The domains crystallized in this study are highlighted by dashed boxes. A sequence conservation map produced by
ClustalX2 is shown for the Bub1CD1 domain. The two sites of phosphorylation (pSer459/pThr461) are highlighted by black arrows. A1: ABBA motif. K1/2: KEN box
motifs. MIM: Mad2 interacting motif. CD1: conserved domain 1. BDD: Bub dimerization domain. GLEBS: Gle2-binding-sequence. TPR: Tetratricopeptide repeat. RLK:
Arg-Leu-Lys motif. RWD: RING, WD40, DEAD domain.
B Three views of the crystal structure of Mad1CTD homodimer (dark/light orange) bound to two Bub1CD1 peptides (purple/blue). The RLK motif of Mad1 is highlighted in
yellow. The two phosphorylation sites are shown as sticks.
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including the first phosphorylation site pSer459 are disordered, and
extend away from the Bub1CD1-Mad1CTD interface (Fig 2B: middle).
Unexpectedly, the peptide binding interface lies diagonally across
the Mad1CTD coiled-coil, making contacts with both Mad1CTD mono-
mers (Fig 2B: left and right panels). The start of the CD1 helix
begins with the phosphothreonine residue (pThr461), contacting the
coiled-coil of one monomer at the conserved Mad1 RLK motif,
whereas its C-terminus contacts the opposite Mad1 subunit at the
top of the coiled-coil and its adjoining head domain b-sheet
(Fig 3A–C). The three C-terminal residues of the peptide are disor-
dered (Fig 3A).
Examination of the phosphorylated and unphosphorylated
Bub1CD1 peptides using 1H 1D NMR revealed narrow dispersion of
their amide peaks (Appendix Fig S1A), indicating that both peptides
are unstructured when not bound to Mad1. Previous circular dichro-
ism experiments also suggested that the unbound Bub1CD1 peptide
is unstructured but might have helical propensity that is increased
with Thr461 phosphorylation (Zhang et al, 2017). This indicates that
Mad1 binding induces the Bub1CD1 domain to adopt a helical
conformation, a mechanism which is likely important for the
specificity of the Mad1CTD-Bub1CD1 interaction.
In the complex, Bub1CD1 and Mad1CTD interact in a parallel
orientation (Fig 2B). This together with the extensive contacts of
the C-terminus of the peptide with the head domain of Mad1CTD
has implications for the architecture of the Mad1-Mad2-Bub1-
Cdc20 assembly at kinetochores. Phosphorylation of Mad1CTD by
Mps1, specifically at Thr716, two residues before the C-terminus,
has been proposed to promote an interaction with a basic patch
on the N-terminal tail of Cdc20 (Ji et al, 2017b) (Fig 1A and B). C-
terminal to the Bub1 CD1 site is the ABBA and KEN1 motifs
(Fig 2A), and although the exact role these motifs play in Cdc20
kinetochore recruitment and MCC formation is still debated, our
results suggest that if this model is correct, then the Bub1 CD1
interactions with the head domain of Mad1CTD could have an
effect on the Mad1-Cdc20 interaction, particularly as this Mad1-
Cdc20 interaction was found to be weak (Vleugel et al, 2015; Di
Fiore et al, 2016; Ji et al, 2017b). Together, these multiple interac-
tions of both Bub1 and Mad1 to Cdc20 might be required to prop-
erly reposition Cdc20 for binding to the newly converted closed-
Mad2, a process which is required for efficient MCC assembly
(Luo et al, 2002). Additionally, secondary structure prediction of
Bub1 residues 448-553 suggests the existence of two a-helices
between the CD1 and the ABBA and KEN1 motifs (Buchan &
Jones, 2019) (Appendix Fig S2A). Therefore, an appealing idea is
that additional contacts between Bub1 and the head domain of
Mad1CTD might exist that could be important for proper formation
of the Bub1-Mad1-Cdc20 complex.
The Bub1-Mad1 interaction is mediated by pThr461
Formation of the Bub1-Mad1 complex at kinetochores is dependent
on phosphorylation of Bub1, a targeting mechanism conserved from
yeast to humans (Heinrich et al, 2014; London & Biggins, 2014a;
Silio et al, 2015). A multiple sequence alignment of the Bub1CD1
domain is shown in Fig 2A. In S. cerevisiae, phosphorylation of
Bub1 at Thr453 and Thr455 by Mps1 promotes an interaction with
Mad1CTD, with pThr455 alone being sufficient for this interaction
(London & Biggins, 2014a; Ji et al, 2017b). In humans, the
equivalent phosphorylation sites, Ser459 and Thr461, are also
required (Daub et al, 2008; Asghar et al, 2015; Ji et al, 2017b).
However, Ser459 is first phosphorylated by Cdk1 that then primes
Thr461 phosphorylation by Mps1 (Ji et al, 2017b; Qian et al, 2017).
Similar to yeast, pThr461 alone is sufficient to promote a strong
Bub1-Mad1 interaction, whereas phosphorylation of Ser459 is not
(Ji et al, 2017b; Zhang et al, 2017). However, a S459A mutation
inactivates Bub1-mediated Mad1 kinetochore recruitment, con-
firming that this priming mechanism is critical for Bub1CD1 function-
ality (Zhang et al, 2017).
Our Mad1CTD-Bub1CD1 structure is consistent with these findings.
Specifically, the phosphate group of pThr461 forms a direct interac-
tion with Mad1 through a charged hydrogen bond with Arg617 of
the conserved Mad1 RLK motif (Fig 3C). Additional contacts of the
phosphothreonine with Bub1 His463 result in a change in orienta-
tion of its imidazole sidechain that enables hydrogen bonding with
Ser610 of Mad1. Our structure further reveals that pSer459 does not
contact Mad1; instead, it is part of the disordered N-terminal tail of
Bub1CD1 (Figs 2B and 3A). This further supports the idea that
pThr461 is key to promoting the Bub1-Mad1 interaction, whereas
Cdk1 phosphorylation of Ser459 primes Mps1 phosphorylation at
Thr461.
To further validate the high-resolution structure of Bub1CD1
bound to Mad1CTD, we performed a phosphorus single-wavelength
anomalous dispersion (SAD) experiment (Appendix Table S2). This
clearly showed anomalous density for the phosphothreonine at each
site built in our structure, confirming the positioning of the phos-
phate groups (Appendix Fig S3A and B). In contrast, there were no
clear signals for the phosphoserine, further suggesting it does not
contribute directly to the Bub1CD1-Mad1CTD interaction.
We then investigated the interaction of Bub1CD1-Mad1CTD using
isothermal calorimetry (ITC). We obtained a similar KD to previ-
ously reported binding studies using similar constructs (Ji et al,
2017b; Zhang et al, 2017), with the doubly phosphorylated pSer459-
pThr461 peptide binding to Mad1CTD with a moderate affinity of
2.7  1.2 µM (Fig 4A). Both previous studies found a significant
reduction in binding for a singly phosphorylated pThr461 peptide.
In contrast, we found that the singly phosphorylated peptide bound
with a KD of 3.3  0.3 µM (Fig 4B; Appendix Fig S4A), essentially
identical to the doubly phosphorylated peptide and consistent with
our crystal structure. Our studies therefore suggest that pSer459
does not directly affect the Bub1-Mad1 interaction and supports the
idea that pSer459 is predominantly required for priming Thr461
phosphorylation.
Using ITC, we observed no binding of the non-phosphorylated
Bub1CD1 peptide to Mad1CTD (Fig 4B; Appendix Fig S4B). Addition-
ally, as assessed using NMR spectroscopy, titration of the non-
phosphorylated peptide into 15N-labelled Mad1CTD also failed to
reveal Bub1-Mad1 interactions (Appendix Fig S1B). These results
further confirm the essential role of the pThr461 phosphorylation
site in generating the human Bub1-Mad1 complex.
A striking feature of the pThr461 residue is its position at the
start of the CD1 helix. Here, the phosphate group caps the N-terminus
of the helix, stabilizing the positively charged helix dipole with its
bulky negative charge (Fig 3A and C). The stabilization of a-helices
through compensation of the a-helix macro-dipole by capping resi-
dues is widely recognized (Wada, 1976; Hol et al, 1978; Chakra-
bartty et al, 1993). Our studies reveal how this is regulated by
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phosphorylation and is reminiscent of a-helix stabilization by phos-
phorylation of Ser46 in the bacterial protein HPr (Pullen et al, 1995;
Thapar et al, 1996). Secondary structure prediction suggests that the
helix of unphosphorylated CD1 would start from Thr464, further
hinting that pThr461 helps to stabilize an extended helix
(Appendix Fig S2A). Using ITC, we found that an R617A mutant of
Mad1 severely weakens (3 mM KD), but does not completely abol-




Figure 3. Molecular interactions of the Mad1CTD-Bub1CD1 complex.
A The extensive largely hydrophobic interface of the Mad1CTD-Bub1CD1 interaction is highlighted with the higher occupancy CD1 peptide (purple). The RLK motif of
Mad1 is emphasized in yellow.
B Close-up view of Bub1CD1 interactions with the head domain of Mad1CTD. Hydrogen bonding interactions within 3.5 A are highlighted by black dashes.
C Close-up view of the Mad1 Arg617 and Bub1 pThr461 interaction. An additional contact occurs between the phosphate of pThr461 and Bub1 His463 which then
forms a hydrogen bond with Mad1 Ser610. Additional stabilizing hydrogen bonding occurs between the pThr461 phosphate and the amide nitrogen atoms of Val462,
His463 and Thr464. Hydrogen bonding interactions within 3.5 A are highlighted by black dashes.
D Top view of the conserved RLK motifs of the Mad1 homodimer which are shown as sticks. The sidechains of hydrophobic residues near the RLK site at the surface of
Bub1CD1 are shown as purple sticks which form a hydrophobic pocket.
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contrasts with the complete absence of interactions between
Mad1CTD and the unphosphorylated Bub1CD1 peptide (Fig 4B;
Appendix Figs S1A and S4B). Thus, the phosphate group of pThr461
promotes interactions to Mad1 through direct contacts to Arg617 as
suggested by the crystal structure and by promoting conformational
changes in the Bub1 CD1 motif. Together, this explains how phos-
phorylation by Mps1 creates a highly specific interaction between
Bub1 and Mad1 and allows for finely tuned regulation of mitotic
checkpoint activation.
Phosphorylation of Thr464 within Bub1CD1, three residues C-termi-
nal to the Thr461 phosphorylation site (Fig 3A), has been reported (Ji
et al, 2017b). In vitro analysis suggested that a triply phosphorylate
pSer459-pThr461-pThr464 peptide has a lower affinity for Mad1 than
the doubly phosphorylated peptide (Ji et al, 2017b). This is explained
by our structure because a bulky phosphate at Thr464 would clash
with the Bub1CD1 binding interface of Mad1. Therefore, phosphoryla-
tion at Thr464 could provide a means to negatively regulate the Bub1-





6 of 16 EMBO reports e52242 | 2021 ª 2021 MRC Laboratory of Molecular Biology
EMBO reports Elyse Fischer et al
The role of the Mad1 RLK motif
The RLK motif of Mad1 is essential for Mad1 SAC-dependent kineto-
chore targeting and the site of direct contact with Bub1 (Brady &
Hardwick, 2000; Kim et al, 2012; Heinrich et al, 2014). Except in a
few species, such as C. elegans and X. laevis, the RLK motif is
highly conserved (Appendix Fig S2B). However, until now the exact
role the RLK motif plays in Bub1 binding has been unclear. Guided
by our crystal structure, we investigated the role of individual resi-
dues of the RLK motif.
As previously discussed, the interface between Mad1 and Bub1 is
mediated by a direct interaction between Mad1 Arg617 of the RLK
motif and Bub1 pThr461 (Fig 3C). An alanine mutation of the
Arg617 residue nearly abolishes Bub1CD1 binding by decreasing the
affinity 1,000-fold to the mM range, which confirms the crucial role
of this interaction (Fig 4B and C, Appendix Fig S5A).
A L618A mutation of the RLK motif abolished Bub1 binding
(Figs 3D and 4B and C; Appendix Fig S5B). This mutant had poor
expression compared with wild-type Mad1CTD, aggregated easily,
and eluted more broadly from a size exclusion column (Fig EV1A).
Leu618 lies between the coiled-coil dimerization interface of the
Mad1 homodimer (Fig 3D); however, SEC-MALS verified that the
purified mutant was a dimer (Fig EV1A). We therefore speculate
that this mutant might perturb the Mad1 dimerization interface in
the region of the RLK motif and possibly disrupt the Arg617 interac-
tion with Bub1 pThr461. Furthermore, Leu618 contributes to the
hydrophobic interface of Mad1CTD-Bub1CD1 by forming a hydropho-
bic pocket with neighbouring Phe470 and Ile471 residues on the
outside of the Bub1CD1 helix (Fig 3D). A L618A mutant would there-
fore weaken these hydrophobic interactions. Consequently, the lack
of detectable interaction between Mad1CTD L618A and Bub1CD1
likely results from mis-folding of the Mad1CTD dimer and disrupted
Mad1CTD-Bub1CD1 contacts.
A previously reported kinetochore localization study revealed a
key role for Lys619 of the RLK motif because a single Mad1 muta-
tion at this site was defective in kinetochore targeting (Kim et al,
2012). To our knowledge, no other study has explored the function
of Mad1 Lys619. Surprisingly, in our structure Lys619 of either
Mad1 subunit does not form extensive contacts with Bub1 (Figs 3D
and 4C). As for the apo structure of Mad1CTD, the Lys619 sidechain
reaches across the Mad1CTD dimer to the opposite coiled-coil and
forms only weak contacts with the opposite Bub1CD1 peptide, likely
through a p–cation interaction between Mad1 Lys619 and Bub1
Phe470 (Fig 3D). Substituting Ala for Lys619 moderately reduced
the Bub1CD1-Mad1CTD affinity from 3 to 10 µM (Fig 4B and C;
Appendix Fig S5C). These results suggest that the lysine of the RLK
motif, although important, is not essential for the Bub1-Mad1 inter-
action in vitro and might point to an additional unknown role of
Lys619 in Mad1 kinetochore recruitment.
Bub1CD1 interactions with the Mad1CTD head domain
An important feature of the Bub1CD1-Mad1CTD complex is that the C-
terminus of each Bub1CD1 peptide contacts the top of the coiled-coil
and head domain of Mad1 of the opposite subunit to which the
phosphorylated threonine interacts (Fig 3A and B). We created indi-
vidual or combined alanine substitutions for several of these resi-
dues (Q627, F629, R630, I643, R650; highlighted in Figs 3B and 4C),
and tested to what extent these contacts contribute to the Bub1CD1-
Mad1CTD interaction using ITC (Fig 4B; Appendix Fig S6A–G).
The only individual mutations which had a significant effect on
Bub1CD1 binding were F629A and R630A (Fig 4B and C;
Appendix Fig S6B and C). Phe629 is a buried hydrophobic residue
which contacts Phe629 of the opposite subunit and therefore contri-
butes to the hydrophobic dimerization interface of Mad1CTD. Phe629
also contributes to the hydrophobic interface of the Bub1CD1-
Mad1CTD complex by stacking with Bub1 Phe475 (Fig 3B). A F629A
mutation completely abolished Bub1CD1 binding (Fig 4B;
Appendix Fig S6B). However, we suspect this could be linked to
disruption of the Mad1 conformation since although dimeric
(Fig EV1A), the F629A mutant was poorly expressed and had a
propensity to aggregate. A Mad1 R630A mutant significantly reduced
Bub1CD1-Mad1CTD binding from 2.7 to 10 µM, suggesting an impor-
tant role in mediating Bub1CD1-Mad1CTD interactions (Fig 4B and C;
Appendix Fig S6C). The significant effects of both the F629A and
R630A mutants agree with previous reports in which both mutants
were defective in kinetochore targeting (Ji et al, 2017b).
Although individual alanine substitutions of Gln627, Ile643 and
Arg650 had no noticeable effect on Bub1CD1 binding (Fig 4B and C;
Appendix Fig S6A, D, and E), a triple alanine mutant (termed QRI*)
reduced affinity fivefold (to 14.5 µM) indicating that in combination
they contribute to the Bub1CD1-Mad1CTD interaction (Fig 4B;
◀ Figure 4. In solution, only one Bub1CD1 binds to the Mad1CTD dimer.
A Isothermal calorimetry (ITC) of Mad1CTD binding to doubly phosphorylated Bub1CD1. Bub1CD1 was injected into Mad1CTD in 19 injections of 2 µl, revealing a
dissociation constant (kD) of approximately 2.7 µM and a stoichiometry of 1:1 Mad1CTD dimer to Bub1CD1 peptide.
B Summary of all ITC experiments performed in this study. The KD and stoichiometry (n) values were obtained by averaging at least three experiments. The reported
error values are calculated standard deviations. The mutations of Mad1CTD are highlighted in the Bub1CD1-Mad1CTD crystal structure in (C). Mutants which do not
bind are marked with a dash. Raw data for each ITC reaction are shown in Appendix Figs S5, S6 and S8. SpT* CD1 peptide is a peptide which is phosphorylated at
Thr461 and not at Ser459. QRI** and QRRI** are triple and quadruple mutants of Mad1 which contact the C-terminus of Bub1CD1. The QRI** triple mutant contains
Q627A, R650A and I643A, while the QRRI** quadruple mutant additionally contains R630A.
C The crystal structure of Bub1CD1-Mad1CTD with the Mad1 residues which were mutated in our ITC experiments shown as sticks. Residues from both monomers are
shown. The lower occupancy peptide is shown as blue and the higher occupancy peptide as purple.
D 31P 1D spectra showing phosphorylated Bub1CD1 peptide titrated with an increasing concentration of Mad1CTD dimer. The peptide sequence is shown above with the
two phosphorylated residues highlighted in red. Peaks corresponding to pSer459 and pThr461 are marked with red arrows. The major pSer459 peak represents
pSer459 in a trans Ser-Pro bond, and the minor pSer459 peak (marked grey) represents pSer459 in a cis Ser-Pro bond. In the 1:1 molar ratio of Mad1CTD dimer to
Bub1CD1, the pThr461 peak is significantly line broadened and the pSer459 peak (marked blue) is perturbed. In the 1:2 molar ratio of Mad1CTD dimer to Bub1CD1, in
addition to signal for the bound pSer459, there is reappearance of the original free position of pS459 and unbound pThr461 supporting the presence of unbound
peptide.
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Appendix Fig S6F). A quadruple mutant (termed QRRI*), which
additionally includes the R630A mutation, further reduced the bind-
ing affinity to 25 µM, confirming the significant role of R630A in the
Bub1CD1-Mad1CTD interaction (Fig 4B; Appendix Fig S6G).
Mutation of the hydrophobic MFQ sequence (residues 474-476)
to RRK, located near the C-terminus of Bub1CD1, abolished Bub1CD1
binding to Mad1CTD (Zhang et al, 2017), a finding that confirms the
importance of these residues in mediating Bub1CD1 interactions with
the head domain of Mad1, as revealed by our structure (Fig 3B).
Together, these results suggest that the interactions between the C-
terminus of Bub1CD1 and the Mad1CTD head are important, although
contribute less binding energy than the pThr461:Arg617 interaction.
In relation to the model of the Bub1:Mad1:C-Mad2:Cdc20 complex
at kinetochores shown in Fig 1, it is possible that the contacts of the
C-terminus of the Bub1CD1 peptide with the head domain of Mad1
are primarily important for positioning Cdc20 in close proximity to
the Mad1:C-Mad2 complex.
In solution, only one Bub1CD1 molecule binds the
Mad1CTD homodimer
When investigating the Mad1-Bub1 interaction using ITC, we were
surprised that Bub1CD1 bound to Mad1CTD with a clear stoichiometry
of only one peptide per Mad1 dimer (Fig 4A and B). This is not
consistent with the two Bub1CD1 peptides bound to the Mad1CTD
dimer in our crystal structure. This one Bub1CD1 peptide to one
Mad1CTD dimer stoichiometry was reproducible in eight ITC experi-
ment repeats with wild-type Mad1CTD and Bub1CD1 and in all ITC
experiments with Mad1 and Bub1 mutants where at least three
replicates were performed. The same KD and stoichiometry were
obtained when using a peptide incorporating an N-terminal trypto-
phan residue to ensure accuracy in peptide concentration measure-
ments. Reversing the titrating species by loading peptide into the
calorimeter cell and titrating Mad1CTD resulted in the same stoi-
chiometry (Appendix Fig S4C). Additionally, when we tested
Bub1CD1 binding to longer forms of Mad1 (485–718 and 420–718) in
complex with C-Mad2, which forms a Mad1:C-Mad2 tetramer, the
stoichiometry was still conserved, although there was a slight
decrease in the binding affinity for the tetrameric complexes
(Appendix Fig S4D and E). This indicates that at least for the specific
binding of the Bub1CD1 domain to the Mad1 RLK site, this 1:1 ratio
of Bub1CD1 to Mad1CTD dimer stoichiometry is likely to be conserved
with full-length proteins.
We used NMR spectroscopy to further analyse the stoichiometry
of the Bub1CD1-Mad1CTD interaction in solution to address the
discrepancy between our ITC data and crystal structure. The unique
31P phosphate 1D NMR signals observed for pSer459 and pThr461 in
the phosphorylated Bub1CD1 peptide enabled us to probe its interac-
tion with Mad1CTD (Fig 4D). pSer459 and pThr461 are part of a Ser-
Pro-Thr sequence and the 31P NMR spectrum yielded not only two
distinct signals for the two phosphorylated residues but also a split-
ting of the—subsequently confirmed—pSer459 signal as a result of
the cis-trans proline isomerization of the Ser-Pro amide bond. At a
1:1 ratio of Bub1CD1 to Mad1CTD dimer, the free pThr461 signal
disappeared indicating that pThr461 is a key residue for the Bub1CD1-
Mad1CTD interaction. The pSer459 signal retained all the characteris-
tics of the free species apart from a small shift, suggesting that
pSer459 remains highly flexible and its chemical environment is only
marginally affected by the now bound Bub1CD1 peptide. These results
further confirm the interactions seen in our crystal structure in which
pThr461 mediates contacts to Mad1CTD whereas pSer459 does not.
Increasing the Bub1CD1 concentration to a 2:1 ratio relative to the
Mad1CTD dimer resulted in a complex spectrum with multiple
signals for both phosphorylated residues (Fig 4D). Striking and easy
to interpret were the two signals observed for pSer459 at the bound
and the original free position, indicating that the spectrum was the
overlay of free and bound phosphorylated Bub1CD1 peptide at equiv-
alent stoichiometries. The reappearance of a signal at the chemical
shift position for unbound pThr461 further supports the presence of
unbound peptide. Taken together, our results provide strong
evidence that the preferred binding mode is in a 1:1 ratio of Bub1CD1
to the Mad1CTD dimer. Increasing the Bub1CD1 concentration did not
result in a second binding event.
We also investigated the stoichiometry of the Mad1CTD-Bub1CD1
complex using analytical ultracentrifugation (AUC) sedimentation
equilibrium (Fig EV1B). Mad1CTD at 20 µMwas incubated with either
20 or 40 µM Bub1CD1 peptide. In both cases, the calculated mass was
close to the expected mass of a Mad1CTD dimer bound to a single
Bub1CD1 peptide, further confirming the 1:1 stoichiometry of the
Mad1CTD dimer to the Bub1CD1 peptide observed by NMR and ITC.
Our ITC and sedimentation equilibrium experiments to measure
the stoichiometry of the Mad1CTD-Bub1CD1 interaction were
performed with concentrations of Mad1 at 100 µM or lower, and
titrating Bub1 until a twofold-fourfold molar excess was obtained.
However, our 31P NMR experiments were conducted with around
0.25 to 0.5 mM of each, and still only one binding event was detected.
Our ability to test binding at higher concentration was limited by the
poor solubility of the peptide above 1.5 mM without the addition of
DMSO. DMSO interfered with ITC enthalpy changes and the NMR
signal from DMSO obscured the protein peaks. In contrast, our
Mad1CTD-Bub1CD1 crystal structure was obtained through co-crystal-
lization of Mad1CTD at a final concentration of 0.35 mM and Bub1CD1
at 2.5 mM in 5% DMSO. The use of millimolar concentrations of
peptide, and the presence of DMSO and isopropanol, required for
Mad1CTD-Bub1CD1 crystallization, may explain the association of a
second peptide in the crystallized complex. Notably, the concentra-
tions of Mad1 and Bub1 used for crystallization greatly exceed their
sub-micromolar concentrations at the kinetochore (Faesen et al,
2017). Additionally, the absence of crystal contacts involving the
Bub1CD1 peptide suggests that the 2:2 stoichiometry of the Mad1CTD-
Bub1CD1 complex is not a crystallization artefact.
In our crystal structure, where Bub1CD1 and Mad1CTD are co-
crystallized at concentrations over 100 times the KD and with a
sevenfold molar excess of peptide, we see clear differential occu-
pancy of the peptides in the electron density map and the 2Fo-Fc
omit map (Figs EV2A and C, and D). This suggests that in the crystal
the two peptides display differing affinities for Mad1CTD, despite the
interactions between Mad1CTD and the two peptides being largely
conserved (compare Fig 3A–C with Fig EV2C, and E–G). Crystalliza-
tion of Mad1CTD-Bub1CD1 with a twofold higher peptide concentra-
tion of 5 mM led to a lower resolution structure most likely due to
the twofold increase in DMSO. However, the differential occupancy,
although reduced, was still observed in this structure (Fig EV2B).
Lowering the peptide and/or DMSO concentration resulted in
either an increase in the differential occupancy of the peptides or
crystallization of apo Mad1CTD. We assume one reason for this is
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that in the apo Mad1CTD structure (P6 crystals), the close packing of
Mad1CTD dimers blocks Bub1CD1 peptide binding. Attempts to soak
the Bub1CD1 peptide at high concentration into these apo Mad1CTD
crystals were unsuccessful. We assume that at lower concentrations
of peptide, the tight P6 packing of the apo Mad1CTD is favoured.
We note that fluorescent quantification of budding yeast Bub1
and Mad1 suggested that kinetochores recruit two Mad1:C-Mad2
complexes per Bub1-Bub3 (Aravamudhan et al, 2016). Cellular
concentration studies in mammalian cell culture systems indicated
100 nM of Bub1 and 20 nM of Mad1 (Howell et al, 2004; Luo et al,
2004; Shah et al, 2004). We therefore cannot exclude the possibility
that the Bub1-Mad1 complex presents a different stoichiometry
in vivo; however, our results strongly point towards a mechanism
by which only one Bub1 molecule binds to the Mad1 homodimer.
This has interesting implications for how MCC is catalytically
assembled onto the outer kinetochore. It has been suggested that
Mad1CTD might fold back onto the Mad1:C-Mad2 core to promote
template conversion of Mad2 from an open to a closed state (De
Antoni et al, 2005; Mapelli et al, 2007). If this fold-over model is
correct, it might imply that only one site is either available or
favourable for Bub1 binding. Our model of the Bub1-Mad1-Cdc20
interaction at kinetochores (Fig 1A and B) suggests that only one
Cdc20 molecule can be accommodated at the head domain of Mad1
proximal to the Thr716 phosphorylation site, especially if one side
of the Mad1 head was making contact with the Mad1:C-Mad2 core.
Therefore, this could be another reason only one Bub1 binds.
Altogether, these results led us to examine the Mad1CTD-Bub1CD1
crystal structure in more detail, as well as to further investigate the
Bub1-Mad1 interaction in solution by NMR, to explain why one
peptide would have preferential binding to the Mad1 homodimer.
The Mad1CTD homodimer is asymmetric
The structure of the previously crystallized apo Mad1CTD homod-
imer is markedly asymmetric (Fig EV3A and B) (Kim et al, 2012). In
particular, there is a large asymmetric curvature in the coiled-coil
stem. One coiled-coil a-helix (apoB) is relatively straight whereas its
counterpart (apoA) is significantly bent. Interestingly, this hinge
bending occurs at the RLK motif (Fig EV3C). Aligning the RLK motif
of both subunits of the apo homodimer shows that the head domain
is rotated inwards towards the more bent a-helix (Fig EV3C). This is
due to a change in the angle at which both helices of the coiled-coil
are curved with respect to the head domain, rather than a change in
the confirmation of the head domain itself (Fig EV3D). This asym-
metry of apo Mad1 is also reflected in the relative B-factors, with
the more bent protomer exhibiting higher flexibility (Fig EV3E).
Bub1CD1-bound Mad1CTD also displays a similar type of asymme-
try but to a reduced extent (Fig 5A). One Mad1CTD subunit is
slightly more curved than the other, but there is an overall straight-
ening of the more bent subunit compared with the apo structure
(Fig 5A). However, as for the apo structure, both subunits of the
coiled-coil are strikingly arched to one side (Fig 5B). Significantly,
the side of the coiled-coil which angles inwards comprises the bind-
ing site of the higher occupancy peptide, whereas the lower, partial
occupancy peptide binds to the outside of the bend (Fig 5A and B).
This curvature of the coiled-coil results in stronger engagement of
both the Mad1 head domain and the hydrophobic coiled-coil with
the higher occupancy peptide (Fig 5A and C).
Comparing how each side of the Mad1 head domain engages
with the adjacent peptide shows that there are additional hydro-
gen bond contacts with the C-terminus of the higher occupancy
peptide compared with the lower occupancy peptide (Fig 5C).
Most noticeable are contacts between Bub1 Gln476 and Mad1
Arg650, as well as Bub1 Met474 and Mad1 Gln627 in the higher
occupancy peptide (Fig 5C; purple) which do not exist in the
lower occupancy peptide (Fig 5C; blue). However, because our
ITC experiments show that neither the Arg650 nor Gln627 resi-
dues have a strong influence on the binding of the peptide to
Mad1CTD, it is unlikely that the differential occupancy is solely
the result of how the head domain engages each peptide. More
likely, the differential occupancy is a result of the net effect of
the peptide binding to the inside of the bent coiled-coil, rather
than to the outside of the bend, combined with enhanced
contacts to the head domain.
This asymmetry within Bub1CD1-Mad1CTD homodimer is also
clearly demonstrated by mapping the B-factors onto the structure
(Fig 5D). The side of the homodimer (bound_A and head_B) which
contacts the higher occupancy peptide (high_CD1) has higher rigid-
ity as does the peptide itself. It is therefore probable that this asym-
metry of the Bub1 bound Mad1 homodimer leads to the differential
peptide occupancy seen in our X-ray structure.
Crystallographic packing is unlikely the cause of the asymmetry
present in the apo Mad1CTD and Bub1CD1-bound Mad1CTD struc-
tures. Both the apo and Bub1CD1-bound states are asymmetric, yet
crystallized in different space groups. Furthermore, we obtained
several crystal structures of the Mad1CTD-Bub1CD1 complex using
the same crystallization conditions but in different space groups
(Fig EV4A–G and Appendix Table S1). In each case, the asymmetry
of the homodimer was retained. The asymmetric unit of the
monoclinic space group (P21) comprises two Mad1
CTD-Bub1CD1
complexes (PDB: 7B1H). Both complexes display asymmetry,
however with differing degrees (Fig EV4C–F). In the more asymmet-
ric complex, there is a more marked difference in Bub1CD1 peptide
occupancy, with high occupancy for the peptide bound to the
concave side of the Mad1CTD coiled-coil, and very low occupancy
for the Bub1CD1 peptide bound to the convex side of the Mad1CTD
coiled-coil. It is therefore likely that the asymmetry is intrinsic to the
Mad1CTD homodimer and contributes to the differential occupancy
of Bub1CD1 peptides in our crystal structures. Alignment of all four
Mad1CTD homodimers from the three different space group struc-
tures displays the extent of the flexibility within the Mad1CTD coiled-
coil and head domain (Fig EV4G).
To our knowledge, we are the first to comment on this asymme-
try in Mad1CTD. However, before our study there would have been
no obvious significance for this asymmetry, and the asymmetry of
apo Mad1CTD could have been easily attributed to crystallization
artefacts. Interestingly, the crystal structure of the tetrameric
Mad1485–584:C-Mad2 complex is also asymmetric (Sironi et al, 2002).
The N-terminal coiled-coil of Mad1 undergoes a break where a
linker region (residues 531–539), directly followed by the Mad1
MIM motif, adopts a different confirmation in each Mad1 protomer,
resulting in a significantly asymmetric tetramer. Although the func-
tional significance of this asymmetry was not demonstrated, the
authors hypothesized that the asymmetry might be connected to
Mad2 conversion at kinetochores. An appealing idea is that the
asymmetry of both the Mad1:C-Mad2 tetramer and the flexibly
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Figure 5. Bub1CD1 bound Mad1CTD homodimer is asymmetric.
A Alignment of the RLK motif of opposite subunits of the Mad1CTD-Bub1CD1 structure. The site of alignment is highlighted by the dashed box. In one dimer (coloured
orange), the higher occupancy peptide is depicted as an orange cartoon. In the other dimer (coloured blue), the lower occupancy peptide is depicted as a blue
cartoon. The orange and blue arrows highlight how there is stronger engagement of the head domain with the higher occupancy peptide.
B Alignment of the head domain of opposite subunits of the Mad1CTD-Bub1CD1 structure. In one dimer (coloured orange), the higher occupancy peptide is depicted as
an orange cartoon. In the other dimer (coloured blue), the lower occupancy peptide is depicted as a blue cartoon.
C Comparison of the high and low occupancy Bub1CD1 peptide contacts with the opposite sides of the Mad1 head domain and top of the coiled-coil. Hydrogen bonds
within 3.5 A are shown as black dashes.
D Temperature factors mapped onto the Mad1CTD-Bub1CD1 crystal structure.
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tethered Mad1CTD might have a common function in regulating
MCC assembly at kinetochores.
Bub1 binding leads to substantial conformational changes
in Mad1CTD
NMR spectroscopy was used to gain detailed structural insights into
the Bub1CD1-Mad1CTD interaction in solution based on an
assignment of Mad1CTD backbone resonances. To counteract a
reduction in sensitivity associated with the slow overall tumbling of
the elongated Mad1CTD dimer, we employed relaxation optimized
3D experiments using a uniformly sidechain deuterated 13C,15N-
labelled sample. Backbone HN, N, Ca, Cb resonances for 113 out of
119 non-proline residues were assigned, and their conformation-
dependent secondary chemical shifts confirmed secondary structure





Figure 6. The Bub1-Mad1 interaction characterized by NMR.
A 1H,15N-2D HSQC showing 15N-labelled Mad1CTD with (blue) and without (grey) Bub1 phosphorylated peptide. Peptides were added in excess at 1:2 molar ratio of
Mad1CTD dimer to Bub1CD1. Assignments of the backbone resonances of Mad1CTD are labelled on the spectra. Close-up of the chemical shift perturbations of the
residues in red during Bub1CD1 titration, are shown in Appendix Figs S7 and S8.
B Relative peak intensities (bound/free) of Mad1CTD upon Bub1CD1 binding. Peak intensities were normalized to that of the C-terminal residue Ala718.
C Relative peak intensities of Bub1CD1-bound Mad1CTD in B are mapped onto the Bub1CD1-Mad1CTD crystal structure. Residues are coloured in a scale of blue to grey,
where regions with the most significant line broadening are highlighted in blue.
D 15N{1H}-heteronuclear NOE values were collected with interleaved on- (I) and off- (I0) resonance and expressed as I/I0. A higher value indicates higher rigidity of the
backbone N–H bond. The Mad1 RLK motif is highlighted in red. The error bars are the calculated standard deviations of two technical replicates on the same sample.
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For the analysis of residues involved in peptide binding, unla-
belled phosphorylated Bub1 peptide was added to 15N-labelled
Mad1CTD. We observed a substantial attenuation for resonances
corresponding to residues 605 to 655 in the 1H,15N correlation
spectra of Mad1CTD (Fig 6A and B; Appendix Figs S7 and S8).
Mapping these line broadened residues onto the crystal structure
of the Bub1CD1-Mad1CTD complex revealed the extent of environ-
mental changes upon peptide binding (Fig 6C). It is important to
note that in general, NMR titrations yield either actual changes in
the chemical shift positions of residues affected or, as found here,
line broadening, especially in situations where binding is in the
lower µM regime. Changes indicate the actual binding site but also
general conformational rearrangements as a consequence of
complex formation. An additional complication arises from the fact
that Mad1 as a dimer only displays one set of signals which indi-
cates conformational exchange between the two monomeric
species. Attenuated signals correspond to most of the coiled-coil
region and two of the b-strands in the head domain (Fig 6C). This
indicates that not only the Mad1 RLK motif is involved in Bub1
binding but also large structural elements of Mad1 experience
changes in their chemical environment. Although the addition of
phosphorylated Bub1CD1 peptide to 15N-labelled Mad1CTD resulted
in major signal attenuations at a molar ratio of 1:1 Mad1CTD dimer
to Bub1CD1 peptide, further addition of peptide did not yield signif-
icant additional changes (Fig EV5A and B). This supports the 1:1
Bub1CD1 to Mad1CTD dimer stoichiometry observed in our ITC, 31P
NMR and sedimentation equilibrium experiments and argues
against a second binding site in solution.
A 15N{1H}-heteronuclear NOE experiment that samples 15N
backbone dynamics on a fast picosecond time scale revealed the
RLK motif of free Mad1CTD as the most flexible segment of the
coiled-coil region (Fig 6D). This supports the idea that this motif
acts as a dynamic hinge resulting in a bend within the apo coiled-
coil region and most likely also in the bound structures. Although it
is conceivable that complex formation with Bub1CD1 will result in
dynamic changes, substantial line broadening of the Bub1CD1-bound
Mad1CTD prevented us from obtaining dynamic data for the
complex. Nevertheless, one can speculate that upon interaction with
Bub1, the rigidity of the RLK motif increases and this in turn would
result in an increase in the overall rigidity of the coiled-coil.
Altogether, our NMR data suggest dynamic changes and local
conformational rearrangements within Mad1CTD upon Bub1CD1
binding. This is consistent with the multiple contacts observed in
the Mad1CTD-Bub1CD1 structure. In particular, the substantial line
broadening observed in the coiled-coil region can be explained by
the fact that the peptide is bound diagonally across the Mad1CTD
coiled-coil and therefore makes extensive contacts with both subu-
nits. With the effect of Bub1 binding experienced in nearly the entire
coiled-coil region, it is conceivable that a conformational rearrange-
ment in the bend of the coiled-coil region of the apo Mad1CTD is a
requirement for efficient Bub1CD1 binding.
Mad1 asymmetry likely controls Bub1CD1 binding stoichiometry
To assess whether the conformation of the apo Mad1CTD crystal
structure is compatible with Bub1CD1 binding, we superimposed the
apo and Bub1CD1-bound Mad1CTD molecules by aligning them on
the RLK motif of each subunit (Appendix Fig S9). A total of four
alignment combinations are possible. Alignments placing either of
the two bound Bub1 peptides on the concave side of the apo struc-
ture coiled-coil cause severe clashes (Appendix Fig S9A and C),
whereas contacts between either peptide and the Mad1CTD head
domain are lost on the convex side, especially for the higher occu-
pancy peptide (Appendix Fig S9B and D). This analysis therefore
indicates that Bub1CD1 is unable to interact with the apo conforma-
tion of Mad1CTD seen in the crystal structure.
A transition of Mad1CTD to a more symmetric state, involving a
conformational change centred on the flexible RLK motif, straighten-
ing the coiled-coil, allows Bub1CD1 binding. Such a conformation,
observed in our Mad1CTD-Bub1CD1 crystal structure, is consistent
with the conformational changes occurring to Mad1CTD upon Bub1
binding in solution, as detected by NMR (Fig 6). The higher the
occupancy the peptide of the Mad1CTD-Bub1CD1 crystal structure is
indeed the one at the concave side of the coiled-coil forming more
contacts to the Mad1CTD head domain, consistent with mutagenesis
and ITC data (Appendix Fig S6). Thus, this peptide is likely to bind
with higher affinity and to represent the single binding peptide in
solution as detected by NMR, ITC and AUC analyses. This model is
supported by our Mad1CTD-Bub1CD1 structures from various space
groups where higher occupancy of the second Bub1CD1 peptide
correlates with a more symmetric Mad1CTD dimer (Fig EV4).
Discussion
This study provides insights into the mechanism of how the Mad1:
C-Mad2 complex is targeted to kinetochores in response to SAC acti-
vation, a process regulated by a sequential Mps1-dependent phos-
phorylation cascade (Fig 1). Cdk1 and Mps1 phosphorylate the
Bub1 CD1 domain to create a direct interaction with the C-terminus
of Mad1. Our Mad1CTD-Bub1CD1 crystal structure explains the
molecular interactions of this highly specific targeting mechanism.
We find that the first Bub1 phosphorylation site, pSer459, does not
make direct contact with Mad1, consistent with the suggested mech-
anism by which Cdk1 phosphorylation of Ser459 primes Mps1 phos-
phorylation of Thr461 (Ji et al, 2017b). We show that pThr461
directly binds to Mad1 Arg617 of the conserved RLK motif, and we
suggest that the high specificity of this interaction results from the
ability of the phosphate of pThr461 to stabilize the N-terminal a-
helix dipole of Bub1CD1. Using a variety of biophysical techniques,
we determined that only one Bub1CD1 peptide binds to the Mad1CTD
homodimer in solution. Analysis of apo and bound Mad1CTD crystal
structures indicates that the homodimer is intrinsically asymmetric,
whereby the Mad1CTD coiled-coil has significant curvature which
also causes stronger engagement of the head domain with the
peptide bound to the side of the coiled-coil with the concave bend.
We suggest that this asymmetry is the reason only one peptide binds
in solution. This also explains the differential occupancy of the two
peptides bound to the Mad1CTD homodimer in our crystal structure.
The use of millimolar concentrations of peptide, and the presence of
DMSO and isopropanol, required for Mad1CTD-Bub1CD1 crystalliza-
tion, may explain the association of a second peptide in the crystal-
lized complex. Altogether, we propose that the asymmetry of the
Mad1CTD-Bub1CD1 complex is an intrinsic and functional feature that
plays an important role in generating the correct juxtaposition of
SAC proteins required to catalyse MCC assembly.
12 of 16 EMBO reports e52242 | 2021 ª 2021 MRC Laboratory of Molecular Biology
EMBO reports Elyse Fischer et al
Materials and Methods
Cloning, expression and purification of Mad1CTD
The coding region of Mad1597–719 was cloned by USER (NEB) into
a modified pRSFDuet-1 vector (71341-3, Sigma-Aldrich) with an N-
terminal double Strep His6-tag, followed by a tobacco etch virus
(TEV) protease cleavage site (Demple & Linn, 1982; Bitinaite et al,
1992). Mad1 mutants were generated using the QuikChangeTM Light-
ning Site-Directed Mutagenesis Kit (Agilent), developed by Strata-
gene Inc. (La Jolla, CA) (Nøhr & Kristiansen, 2003). Mad1
constructs were transformed into RosettaTM 2 (DE3) SinglesTM
Competent Cells (71400, Novagen) for expression. Expression was
induced with 0.5 mM IPTG and grown overnight at 18°C. Cells were
lysed in 25 mM HEPES pH 8.1, 250 mM NaCl, 2 mM DTT, 5% glyc-
erol, 2 mM EDTA supplemented with lysozyme, and CompleteTM
EDTA-free protease inhibitors (Roche). Proteins were purified over
a Strep-Tactin Superflow Plus column (QIAGEN) and cleaved with
TEV protease overnight at 4°C. The cleaved Mad1CTD was then
diluted to 50 mM NaCl, purified over an anion exchange (Resource
Q, GE Healthcare) column, followed by size exclusion chromatogra-
phy using a Superdex 75 Increase column (GE Healthcare). Mad1CTD
was concentrated to 35 mg/ml in a buffer of 20 mM HEPES pH 7.5,
100 mM NaCl and 1 mM TCEP.
Peptide synthesis
Bub1CD1 peptides were ordered from Designer Bioscience UK, at
95% purity. The full peptide sequence used in this study was (W)
KVQP{pS}P{pT}VHTKEALGFIMNMFQAPTS. (W) = peptide with
an additional N-terminal tryptophan was used to confirm peptide
concentration in stoichiometry studies.
Isotopic labelling of Mad1CTD
Isotopically labelled Mad1CTD was expressed in M9 minimal media
(6 g/l Na2HPO4, 3 g/l KH2PO4, 0.5 g/l NaCl) supplemented with
1.7 g/l yeast nitrogen base without NH4Cl and amino acids (Sigma
Y1251). 1 g/l 15NH4Cl and 4 g/l unlabelled glucose were supple-
mented for 15N labelling. For the deuteration of nonlabile sidechain
protons, cells were adapted for growth in 10, 44 and 78% deuter-
ated media on agar plates before they were grown in large cultures
supplemented with 1 g/l 15NH4Cl and 4 g/l
2H13C-glucose in 99%
D2O (Sigma). Prior to NMR experiments, isotopically labelled
Mad1CTD and Bub1CD1 peptide were dialysed into 25 mM HEPES,
pH 7.0, 100 mM NaCl, 1 mM TCEP.
NMR spectroscopy
1H-detected experiments were performed on 600 and 800 MHz
Avance III spectrometers, both equipped with triple resonance TCI
CryoProbes (Bruker). 31P 1D NMR spectra were recorded on a
500 MHz Avance II spectrometer equipped with a broadband BBO
cryoprobe (Bruker). All spectra were collected in 50 mM HEPES,
pH 7.0, 100 mM NaCl, 2 mM TCEP, 0.02% NaN3 at 298K. Standard
2H decoupled TROSY-based triple resonance experiments were
used for backbone resonance assignments: HNCO, HN(CA)CO,
HNCA, HN(CO)CA, HNCACB, HN(CO)CACB and HN(COCA)NNH
(Pervushin, 2020). Backbone datasets were collected with 20–25%
non-uniform sampling and reconstructed using compressed sensing
in MddNMR (Mayzel et al, 2014). Topspin 3.6 (Bruker) was used
for processing and NMRFAM-Sparky 1.47 for data analysis (Lee
et al, 2015). Backbone assignments were obtained in Mars (Jung &
Zweckstetter, 2004). Secondary chemical shifts were calculated
from the differences between observed Ca/Cb chemical shifts and
Ca/Cb chemical shifts for random coils (Kjaergaard & Poulsen,
2011). For binding studies, the relative peak intensities were
normalized to the C-terminal residue Ala718 of Mad1CTD and
expressed as PIbound/PIfree, with PIbound and PIfree being the peak
heights of the free and bound forms, respectively. 15N{1H}-
heteronuclear NOE values are expressed as I/I0 ratio and measured
using standard Bruker pulse sequences, with interleaved on- (I) and
off-resonance (I0) saturation.
31P 1D spectra were recorded using a
standard 1H-decoupled sequence with power-gated decoupling and
30 flip angle.
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) was performed using an Auto-
iTC200 instrument (Malvern Instruments, Malvern, UK) at 20C.
Mad1CTD and Bub1CD1 peptide mutants were dialysed into 20 mM
HEPES pH 7.5, 100 mM NaCl, 1 mM TCEP. For each titration
between 30–100 µM of Mad1 was pipetted into the calorimeter cell.
The Bub1CD1 peptides at 0.3–1.5 mM were titrated into the cell
consisting of one 0.5 µl injection followed by 19 injections of 2 µl
each. The changes in the heat released were integrated over the
entire titration and fitted to a single-site binding model using the
MicroCal PEAQ-ITC Analysis Software 1.0.0.1258 (Malvern Instru-
ments). Titrations were performed in triplicate. Calculations for stoi-
chiometry were based on the molar concentrations of dimeric
Mad1CTD.
SEC-MALS
Size exclusion chromatography coupled with multi-angle static light
scattering (SEC-MALS) was performed using an Agilent 1200 series
LC system with an online Dawn Helios ii system (Wyatt) equipped
with a QELS+ module (Wyatt) and an Optilab rEX differential refrac-
tive index detector (Wyatt). 100 ll purified protein from 0.5–
2.0 mg/ml was auto-injected onto a Superdex 200 Increase 10/300
GL column (GE healthcare) and run at 0.5 ml/min. The molecular
masses were analysed with ASTRA 7.3.0.11 (Wyatt). Data were
plotted using Prism 8.4.3 (GraphPad Software, Inc).
Analytical ultracentrifugation
Mad1CTD was mixed with Bub1CD1 peptide to give final concentra-
tions of 20 µM Mad1CTD with either 20 or 40 µM Bub1CD1 in 20 mM
HEPES pH 7.5, 100 mM NaCl, 1 mM TCEP. Samples were loaded
into 12 mm 6-sector cells, placed in an An50Ti rotor and centrifu-
gated at 10,200, 12,200 and 21,000 rpm at 20°C until equilibrium
had been reached using an Optima XL-I analytical ultracentrifuge
(Beckman). The data were analysed in SEDPHAT 15.2b (Schuck,
2003). The partial-specific volumes (v-bar) were calculated using
Sednterp (Cole et al, 2008). The density and viscosity of the buffer
were determined with a DMA 4500M density meter (Anton Parr)
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and a AMVn viscometer (Anton Paar). Data were plotted with the
program GUSSI (Brautigam, 2015).
Crystallization
Purified Mad1CTD at 11 mg/ml in 20 mM HEPES pH 7.5, 100 mM
NaCl and 1 mM TCEP was mixed for 10 mins with Bub1CD1 peptide
dissolved into 100% DMSO at 50 mM starting concentration such
that the final concentration of Bub1CD1 was 5 or 2.5 mM Bub1CD1 in
either 10 or 5% DMSO, respectively. Sample was trialled in several
sparse matrix screens using the sitting-drop vapour diffusion
method at 21°C (Jancarik & Kim, 1991; Gorrec, 2016). Crystal hits
were obtained in Hampton Research Crystal Screen 1 (HR2-110),
10% isopropanol, 0.1 M Na HEPES pH 7.5, 20% PEG 4000. Crystal
growth was optimized using this condition and a drop size of 500 nl
of 1:1 protein to reservoir solution. The crystals were harvested
within 48 h and flashed cooled in liquid nitrogen using the reservoir
solution supplemented with 20% glycerol.
Crystallographic data collection, structure determination
and refinement
Data were collected at beamline I04 at the Diamond Light Source,
U.K. Selected data sets were autoprocessed using the XDS pipeline
in Xia2 (Kabsch, 2010; Winter, 2010).
Phenix version 1.18.2-3874 was used for structure solution with
PHASER-MR molecular replacement against PDB: 4DZO (Kim et al,
2012; Liebschner et al, 2019). The peptide ligand was manually built
in Coot (Emsley et al, 2010). Refinement was performed using
PHENIX and validation with MolProbity (Williams et al, 2018).
Single-wavelength anomalous dispersion
The crystals were harvested using LithoLoop sample mounts on
specialized I23 copper sample assemblies. Data were collected on
the long-wavelength beamline I23 at Diamond Light Source at X-ray
energy of 4.5 keV using the semi-cylindrical PILATUS 12M (Dectris,
CH) (Wagner et al, 2016). 4.5 keV (2.775 A) was selected as this
energy provides a good balance of increased signal from P and S
atoms and reduced X-ray absorption by the crystal and solvent.
Each data set consisted of 360° with an exposure time of 0.1 s per
0.1° image. Multiple data sets per crystal were taken at varying
kappa and phi values to ensure completeness and increase multi-
plicity. Data integration was performed with XDS and XSCALE (Kab-
sch, 2010). The origin of the PDB model was corrected using
POINTLESS, AIMLESS and MOLREP (Evans, 2005; Winn et al,
2011). Phased anomalous difference Fourier maps were produced
using ANODE (Thorn & Sheldrick, 2011). A sigma cut-off of 4.0 was
used to identify sites of anomalous contribution.
Molecular graphics
Molecular analyses and structure alignments were performed with
the UCSF Chimera package (Pettersen et al, 2004). Chimera is devel-
oped by the Resource for Biocomputing, Visualization, and Infor-
matics at the University of California, San Francisco (supported by
NIGMS P41-GM103311). Molecular graphics were produced in
PyMOL Molecular Graphics System, version 2.3.3 Schrödinger, LLC.
Data availability
The NMR assignments were deposited to the BMRB database
(http://www.bmrb.wisc.edu/) and assigned the accession number
BMRB ID: 50602. The Mad1CTD-Bub1CD1 coordinates have been
deposited to the PDB with the identification codes, 7B1F (P212121),
7B1H (P21) and 7B1J (P21212).
Expanded View for this article is available online.
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